Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137819) titled 'Phase 3 - Evaluation of Veregen(R) 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Aresus Pharma GmbH
Condition:
Actinic Keratosis of Face and Scalp
Intervention:
Drug: Topical treatment
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: September 4, 2024
Target Sample Size: 280
Countries of Recruitment:
Germany
To know more, visit https://cl...